NVO250117C45000
- 86.65
- 0.000.00%
Novo-Nordisk A/S Newsroom
European stock markets have given back their gains as the impact of tariff reports fades.
European stock markets gave back gains on Tuesday afternoon due to a significant decline in Medical Care stocks, which offset the boost from cooling wholesale inflation data in the USA and the possibility that the Donald Trump administration may gradually increase trade tariffs. By the close in London, the Europe Stoxx 600 Index had fallen by 0.1%, having risen as much as 0.6% during the session. The weak Earnings Reports from Eli Lilly and Co dragged down the performance of comparable Medical Care stocks in Europe, with Novo-Nordisk A/S stock price falling to its lowest since the disappointing latest report released on December 20. The Energy Sector also lagged, with BP PLC stock price declining, after the company indicated that its Business generally performed weakly in the fourth quarter. According to Bloomberg News,
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Hims & Hers in Focus as Eli Lilly GLP-1 Sales Disappoint
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.
Mounjaro and Zepbound Sales Disappoint, and Eli Lilly's Stock Is Dropping
Novo Nordisk Shares Are Trading Lower in Sympathy With Eli Lilly Which Issued FY24 Revenue Guidance Below Estimates.
Obesity Drug Developer Metsera Files for $100M IPO
Dividend Aristocrats Can't Handle Rising Rates. These Are Better Income Bets. -- Barrons.com
Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $124
The world's first oral GLP-1 receptor agonist, Novo-Nordisk A/S, has been fully launched in China.
On January 11, Gelonghui reported that Novo-Nordisk A/S announced the comprehensive launch of its Innovative Drug, Ozempic (semaglutide tablets), in China today. As the first oral GLP-1RA, Ozempic combines SNAC technology to achieve significant benefits such as lowering blood sugar, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will improve patient adherence, creating a new era in the treatment of type 2 diabetes, helping achieve quality blood sugar targets and comprehensive metabolic management, bringing new hope to 0.14 billion diabetes patients in China.
Express News | Novo-Nordisk A/S is confident in the economic prospects of China and its development in the country, and is willing to continue investing in the Chinese market.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
U.S. stocks are experiencing fluctuations | Novo-Nordisk A/S (NVO.US) is rising nearly 2% against the trend while developing weight-loss drugs using AI.
On Friday, Novo-Nordisk A/S (NVO.US) rose nearly 2% against the trend, closing at $86.77.
Novo Holdings Invests in $200M Series A for Windward Bio Launch to Advance Long-acting Treatments for Asthma and COPD
Novo Nordisk Still a Buy, But Patience May Be Needed -- Market Talk
U.S. Stock Outlook | Non-farm payroll data exceeded expectations, leading to a short-term plunge in the three major futures indices; high-performing stocks surged, with pharmacy stock WBA rising over 13% in pre-market, and Delta Air Lines climbing over 9%
NVIDIA slightly fell before the market opened, and AMD dropped over 2% before the market opened, as the USA plans to tighten the export of AI Chips from NVIDIA and AMD; several Federal Reserve voting members have spoken out, hinting at a pause in interest rate cuts; sources say that the USA Treasury is expected to release a statement detailing new sanctions on Russian oil later on Friday.
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Euro Stocks Can Offer a Lesson in High Concentration for the U.S. – Goldman